Background: The current standard therapy for chronic hepatitis C is pegylated interferon (PEG-IFN) plus ribavirin (RBV) combination therapy. Recently, it has been reported that amino acid (aa) substitutions in the core region, as well as the IFN-sensitivity-determining region (ISDR), were predictive of non-virological response (NVR), sustained virological response (SVR) and early virological response. Despite the importance of these two predictive factors for combination therapy, their interaction is poorly understood. Methods: A total of 117 patients who were treated with PEG-IFN-a2b plus RBV combination therapy were selected for participation in this study. We determined the aa sequences in the core region and ISDR by direct sequencing and analysed them along with clinical data to indentify predictive factors for therapeutic response.
HCV is one of the most serious global health problems, affecting >170 million people worldwide [1] [2] [3] . Chronic HCV infection leads to development of chronic hepatitis, cirrhosis and hepatocellular carcinoma [4] [5] [6] [7] [8] . In an attempt to eradicate the virus and prevent the development of advanced liver diseases and hepatocellular carcinoma, interferon (IFN) is administered to patients with chronic HCV infection, with success in a subset of patients in whom marked biochemical and histological improvements can be obtained [9, 10] . However, patients with high virus titres who are infected with genotype 1b, which is the major genotype, affecting approximately 70% of Japanese HCV patients, show poor response to IFN monotherapy. Less than 20% of patients treated with IFN monotherapy show sustained virological response (SVR) [11] [12] [13] [14] . With the advent of pegylated interferon (PEG-IFN) and a newer antiviral agent, ribavirin (RBV), the eradication rate of the virus has improved overall. However, the eradication rate of
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Amino acid substitutions in core and NS5A regions of the HCV genome can predict virological decrease with pegylated interferon plus ribavirin therapy Shosuke Kitamura 1, 2 , Masataka Tsuge 1, 2, 3 , Tsuyoshi Hatakeyama 1, 2 , Hiromi Abe 1 , Michio Imamura 1, 2 , Nami Mori 2, 4 , Hiromi Saneto 1, 2 , Tomokazu Kawaoka 1, 2 , Fukiko Mitsui 1, 2 , Nobuhiko Hiraga 1, 2 , Shintaro Takaki 1, 2 , Yoshiiku Kawakami 1, 2 , Hiroshi Aikata 1, 2 , Shoichi Takahashi 1, 2 , Waka Ohishi 1, 5 , Hidenori Ochi 1, 2 , C Nelson Hayes 1, 2 , Kazuaki Chayama 1,2 * Introduction genotype 1b with high viral load still remains only 40-50% [15] [16] [17] . Many host and viral factors that are predictive of the response to PEG-IFN plus RBV combination therapy have been reported to date. The SVR rate of the combination therapy has been reported to be significantly lower in older patients and in female patients [18] [19] [20] [21] [22] . The SVR rate was only 30% in female genotype 1b patients older than 65 years who have high viral loads [23] . Recently, sequencing analysis of HCV genomes has been actively performed to predict the effects of PEG-IFN plus RBV combination therapy. According to sequence analysis of HCV hypervariable region 1, quasispecies in this region at baseline were related to early virological response (EVR) and virological rebounds following combination therapy [24] . It has also been reported that the number of amino acid (aa) substitutions in the IFN-sensitivity-determining region (ISDR; nucleotides 2209-2248 or aa positions 237-276 of the NS5A region) correlates with SVR rate for combination therapy in HCV genotype 1b patients [25] . Recently, Akuta et al. [18, 19, 26, 27] reported that the presence of aa 70 and/or aa 91 substitutions in the HCV core region is an independent and significant predictor of virological response (VR; for example, EVR, SVR and non-virological response [NVR] ) to combination therapy. Okanoue et al. [28] also reported that the wild-type HCV core aa 70 and ≥2 aa substitutions in the ISDR are useful predictive factors for SVR. These reports, however, did not analyse the interaction of aa substitutions in the core region and the ISDR.
We recently analysed aa substitutions in the HCV core region and ISDR from patients treated with conventional IFN-a2b and RBV combination therapy and showed that substitutions in the core region and ISDR are useful predictive factors of response to therapy [29] . To date, no report has precisely analysed the relationship between both of these viral and clinical factors in patients who received PEG-IFN plus RBV combination therapy. In the current study, we analysed the relationship between clinical background and aa substitutions in the core region and ISDR to clarify the predictive factors of VR to combination therapy.
Methods

Patients
A total of 353 adult Japanese patients infected with HCV genotype 1b provided written informed consent to participate in the present study at Hiroshima University Hospital (Hiroshima, Japan). Among these patients, 117 who were treated with the PEG-IFN-a2b plus RBV combination therapy from August 2004 to June 2008, were selected as study participants based on the following criteria: serum HCV RNA titre >5.0 log 10 IU/ ml using HCV RNA quantitative analysis with Amplicor™ PCR analysis (Roche Diagnostics, Indianapolis, IN, USA; HCV RNA>5.0 log 10 IU/ml was included in the category of high viral load based on guidelines by the Ministry of Health, Labor and Welfare [MHLW] of Japan [30] ); no coinfection with other viruses, such as HIV or HBV; no other liver diseases, such as alcoholic liver disease, autoimmune hepatitis or decompensated cirrhosis (alcoholic liver disease was defined as patients with a lifetime total ethanol intake >100 kg [31] ); and no coexisting conditions, such as poorly controlled diabetes mellitus, decompensated renal disease, preexisting psychiatric disease, seizure disorders, cardiovascular disease, haemophilia, autoimmune diseases or post-transplantation. All selected patients were followed until 6 months after the completion of combination therapy. Overall, 56 of 117 patients had received prior antiviral treatments, such as IFN monotherapy or IFN plus RBV combination therapy, but they had never previously received PEG-IFN-a2b monotherapy or PEG-IFN-a2b plus RBV combination therapy. The experimental protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the Hiroshima University Hospital ethical committee. Baseline clinical characteristics of the 117 patients are shown in Table 1 .
Patients were injected weekly with 1.5 µg/kg of PEG-IFN-a2b (PegIntron ® ; Schering-Plough, Kenilworth, NJ, USA) subcutaneously and were administered oral RBV (Rebetol ® ; Schering-Plough) daily for 48 weeks. The initial dose of RBV was adjusted according to body weight following the standard Japanese regimen (600 mg/day for ≤60 kg, 800 mg/ day for 60-80 kg and 1,000 mg/day for >80 kg) [30] . Adverse events were monitored clinically by careful Determination of aa sequences in the HCV core region and ISDR HCV RNA was extracted from 100 µl of stored serum samples by SepaGene RV-R (Sanko Junyaku Co., Ltd, Tokyo, Japan) and dissolved in 20 µl of H 2 O and converted to complementary DNA by RT with random primers and Moloney murine leukaemia virus RT (Takara Shuzo, Tokyo, Japan). The complementary DNA was then amplified by nested-PCR to determine the nucleotide sequences in the HCV core region. The PCR protocol involved initial denaturation at 95°C for 5 min, 35 cycles of denaturation for 30 s at 94°C, annealing of primers for 1 min at 57°C and extension for 1 min at 72°C, followed by final extension at 72°C for 7 min. The primers for the first-round PCR were cc11 (forward 5′-GCC ATA GTG GTC TGC GGA AC-3′) and e14 (reverse 5′-GGA GCA GTC CTT CGT GAC ATG-3′), and the primers for the second-round PCR were cc9 (forward, 5′-GCT AGC CGA GTA GTG TT-3′) and e14 (reverse), as previously described [18, 27, 32, 33] . To determine the nucleotide sequences of the HCV ISDR, we also performed RT nested-PCR with the same protocol as in the HCV core region. The primers used were IM11 (forward 5′-TTC CAC TAC GTG ACG GGC AT-3′) and 5A02KI (reverse 5′-CCC GTC CAT GTG TAG GAC AT-3′) for the first-round PCR and 5A05KI (forward 5′-GGG TCA CAG CTC CCA TGT GAG CC-3′) and IM10 (reverse 5′-GAG GGT TGT AAT CCG GGC GTG C-3′) for the secondround PCR. After amplification, the final PCR products were separated in 2% agarose gel and purified with the QIAquick gel extraction kit (Qiagen GmbH, Hilden, Germany). Sequence analysis was performed using the ABI Prism 3100 Avant Genetic Analyzer (Applied Biosystems, Foster City, CA, USA). Nucleotide sequences were compared with the nucleotide sequences of genotype 1b HCV-J (GeneBank accession number D90208) [34] .
To analyse the relationship between the aa substitutions in the core regions, we divided the study participants into four groups on the basis of the presence of mutant (M) and wild-type (W) substitutions as follows: coreMM included patients with both aa 70 and aa 91 substitutions in the core region; coreMW included patients with only an aa 70 substitution in the core region; coreWM included patients with an aa 91 substitution in the core region; and coreWW included patients with neither aa 70 nor aa 91 substitutions in the core region. To analyse the effect of aa substitutions in the ISDR, we divided the patients into two groups as follows: ISDR≥1 included patients with ≥1 aa substitutions in the ISDR and ISDR0 included patients with no aa substitutions in the ISDR.
Statistical analyses
The baseline characteristics of the patients in the two groups were compared and the differences were assessed by χ 2 test with Yate's correction, Fisher's exact probability test and the Mann-Whitney U test. All P-values <0.05 by two-tailed test were considered statistically significant. To determine the predictors of VR, univariate and multiple logistic regression analysis was performed. Variables with statistical significance (P<0.05) or marginal significance (P<0.10) in univariate analysis were retained for multiple logistic regression to identify significant independent predictive factors. Statistical analyses were performed using SPSS version 17.0 (SPSS Inc., Chicago, IL, USA).
Results
Core region and ISDR aa sequences, and their relationship with clinical parameters
To analyse the relationship between clinical background and aa sequences of the core region and ISDR, we compiled the clinical backgrounds of 117 patients who were treated with PEG-IFN-a2b plus RBV combination therapy for 48 weeks (Table 1 ). The amount of PEG-IFN-a2b injection was reduced in 48 of 117 patients because of moderate or severe thrombocytopaenia and/or neutropaenia during the course of combination therapy. The dose of RBV was also reduced in 55 of 117 patients because of progression of anaemia, but none of the study patients received erythropoietin or blood transfusions during treatment. In total, 19 patients failed to complete the 48-week treatment because of very poor reduction of HCV RNA, and these patients were categorized as NVR; however, none of the study patients discontinued treatment because of adverse effects. We analysed the nucleotide and aa sequences of the core region and ISDR. In these 117 patients, core aa 70 (R70Q/Y/H) and core aa 91 (L91M) substitutions were observed in 48 (41.0%) and 61 (52.1%) patients, respectively. A marginal association was observed between the sequences of core aa 70 and core aa 91 (P=0.0920; Figure 1A ). For the aa sequence of the ISDR, the wild-type was the most frequently detected sequence, and the frequency decreased as the number of aa substitutions increased ( Figure 1B) . We then evaluated the relationship between the aa substitutions of the core region and the ISDR ( Figure 1C) . The Breslow-Day test showed no heterogeneity in core mutation patterns between patients with or without aa substitutions in the ISDR (P=0.84). We then compared the clinical parameters and core region aa substitution patterns. There was no relationship between age or gender and aa patterns of the core region (SK et al., data not shown).
Clinical and virological predictive factors for VR and NVR to the combination therapy
Statistical analysis was used to compare VR and NVR patients in order to identify predictive factors for response to PEG-IFN-a2b plus RBV combination therapy. Among the clinical background factors, only serum γ-glutamyl transpeptidase (GTP) levels differed significantly (P=0.0032), and of the virological factors, core aa 70 and aa 91 substitutions were significantly (P<0.001) and marginally significantly (P=0.053) associated with VR (Table 2) , respectively. When core region substitution patterns were compared, the rate of achieving VR decreased in the following order: coreWW, coreWM, coreMW and coreMM ( Figure 2A ). By contrast, no association was found between ISDR substitutions and VR (Table 2) ; however, a significantly lower number of patients with core aa pattern MM and no ISDR substitutions achieved VR ( Figure 2B ). In addition, the patients who had core aa pattern MM with ≥1 aa substitutions in the ISDR achieved VR with higher frequency ( Figure 2B ). Similar tendencies were also evident when the clearance rate of the virus over time was compared among coreMM patients versus others ( Figure 2C ) and coreMM/ISDR0 patients versus others ( Figure 2D ). These results showed that the aa sequence of ISDR is useful to discriminate poor responders among coreMM patients. We performed a logistic regression analysis for NVR using γ-GTP levels and substitutions in the core region and ISDR as potential predictive factors. As shown in Table 3 , core aa 70 substitutions (P=0.002) and high γ-GTP levels (P=0.049) were independent predictive factors of NVR. Additionally, logistic regression for NVR was performed using the serum γ-GTP level as a continuous variable. ISDR0 (P=0.038), core aa 70 substitutions (P=0.008) and high γ-GTP levels (P=0.003) were independent predictive factors of NVR. However, when combined with core region aa substitutions, the core aa pattern MM did not increase the strength of association for NVR (SK et al., data not shown). To identify more effective predictors, we analysed the haplotype of the core region and the ISDR. In multivariate analyses of core region and ISDR substitutions, coreMM/ISDR0 was the most significant predictive factor for NVR (Table 4) . These results suggest that the evaluation of aa substitutions in both the core region and the ISDR are useful for predicting poor responders to combination therapy.
Clinical and virological predictive factors for SVR to the combination therapy
Next, we analysed predictive factors for SVR in patients treated with PEG-IFN-a2b plus RBV combination therapy. As shown in Table 5 , some clinical background data, including age, white blood cell count, platelet count and γ-GTP levels, were significantly different between SVR and non-SVR patients in univariate analyses, and neutrophil count was marginally significantly different. Among the viral factors, core substitutions at aa 70 and aa 91 were significantly associated with SVR, but HCV RNA titres and the number of ISDR substitutions were not significantly associated with SVR (Table 5 ). RVR and EVR were also significantly associated with SVR. Liver biopsy was performed in 94 of 117 patients, but no significant association was found between SVR and liver fibrosis (Table 5) . When the pattern of aa substitutions of the core region was compared with SVR, the rate of achieving SVR was significantly higher for coreWW than the other substitution patterns ( Figure 3A) . Remarkably, none of the 
Figure 2. Analysis of factors associated with virological response
(A) Virological response rates were compared between the combinations of the HCV core substitutions. Statistical analysis was performed using the χ 2 test with Yate's correction. A significant difference was found between participants with substitutions in both core amino acid (aa) 70 and aa 91 (coreMM) and each of the other groups. (B) Analysis of participants with coreMM by HCV core plus interferon-sensitivity-determining region (ISDR) haplotypes. Statistical analyses was performed using Fisher's exact probability test. (C&D) The cumulative HCV-RNA-negative rate during 48 weeks of combination therapy was analysed by the log-rank test. Groups were classified based on the presence of HCV core double substitutions (coreMM) and ISDR substitutions. coreMW, substitutions in core aa 70 only; coreWM, substitutions in core aa 91 only; coreWW, no substitutions in either core aa 70 or aa 91; ISDR0, absence of substitutions in the ISDR; ISDR≥1, subsitutions in ≥1 region of the ISDR. patients with coreMM or ISDR wild-type showed SVR ( Figure 3B) . We thus performed a logistic regression analysis for SVR using the following potential predictive factors: age, white blood cell count, platelet count, γ-GTP and aa substitutions in the core region and ISDR (Table 6 ). In this multivariate analysis, we excluded factors such as RVR and EVR to assess the predictive factors before the initiation of combination therapy. As shown in Table 6 , higher platelet count (P=0.002), the core aa pattern WW (P=0.008) and low γ-GTP levels (P=0.013) were independent predictive factors of SVR, but the combination of coreWW and the ISDR≥1 did not increase the odds ratio for SVR (SK et al., data not shown). Additionally, logistic regression analysis for SVR was performed using the continuous values for age, white blood cell count, platelet count and serum γ-GTP level. Younger age (P=0.003), as well as core aa pattern WW (P=0.013) and lower level of γ-GTP (P=0.017), were independent predictive factors of SVR, although the effect of platelet count on SVR decreased (P=0.136).
Factor OR (95% CI) P-value
Discussion
Recently, combination therapy with PEG-IFN and RBV has been introduced for clinical applications, and the efficacy of IFN therapy for chronic HCV infection drastically improved. The SVR rate with PEG-IFN plus RBV combination therapy increased up to 40-50% in patients infected with high viral titre of HCV genotype 1b [15, 17, 35] . However, more than one-half of these patients have not yet been able to achieve SVR with combination therapy. Recently, the relationship between HCV aa substitutions and IFN responses has the χ 2 test. aa, amino acid; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; EVR, early virological response; ISDR0, absence of substitutions in the interferon-sensitivitydetermining region (ISDR); ISDR≥1, substitutions in ≥1 region of the ISDR; M, mutant; RVR, rapid virological response; SVR, sustained virological response; W, wild-type; WBC, white blood cell; γ-GTP, γ-glutamyl transpeptidase.
been extensively analysed in laboratories worldwide. In 1996, Enomoto et al. [36] reported that the number of substitutions in the HCV ISDR was associated with response to IFN monotherapy. They analysed ISDR sequences from 84 Japanese patients chronically infected with HCV genotype 1b and revealed that HCV-infected patients with >4 ISDR substitutions were more sensitive to IFN therapy than those with ≤4 ISDR substitutions. Subsequent supportive studies were reported by several laboratories [37] [38] [39] [40] . Thereafter, with advances in IFN treatment, new evidence on the relationship between HCV aa sequences and IFN response was demonstrated. Akuta et al. [32] reported that the existence of substitutions in the HCV core aa 70 and aa 91 regions was one Figure 3 . Association between the HCV amino acid substitutions and sustained virological response (A) Sustained virological response rates were compared between the HCV core substitution haplotypes. Statistical analysis was performed using the χ 2 test with Yate's correction. A significant difference was found between participants with substitutions in both core amino acid (aa) 70 and aa 91 (coreMM) and each of the other groups. (B) All patients were partitioned into two groups: those with double mutants plus the wild-type interferon-sensitivity-determining region (ISDR; coreMM/ ISDR0) and others. Statistical analysis was performed using Fisher's exact probability test. coreMW, substitutions in core aa 70 only; coreWM, substitutions in core aa 91 only; coreWW, no substitutions in either core aa 70 or aa 91.
Factor
OR (95% CI) P-value of the predictive factors of NVR with IFN plus RBV combination therapy. Okanoue et al. [28] reported that wild-type core aa 70 and the presence of >2 aa substitutions in ISDR were predictive factors for SVR with PEG-IFN-a2b plus RBV combination therapy, but that the core aa 91 substitution was not. In the present study, we analysed the relationship between the HCV aa substitutions (core aa 70, aa 91 and ISDR) and IFN responses among patients who were infected with HCV genotype 1b with a high viral load and who were treated with PEG-IFN plus RBV combination therapy. The early-phase VR, such as RVR and EVR, were significantly associated with clinical background factors, such as age, platelet count and γ-GTP levels, but HCV aa sequences were not (SK et al., data not shown). These results suggest that HCV aa substitutions do not affect the antiviral effect of IFN directly. Our previous report using human hepatocyte chimeric mice might be relevant to this supposition [41] . When the mice infected with our original infectious HCV clone, which was generated from serum infected with HCV genotype 1b [42] , were treated with IFN for 4 weeks, there was no significant difference in HCV reduction between HCV coreWW clone and coreMM clone (NH et al., unpublished observations). Our clinical data also suggested by sequence analysis that HCV could not develop IFN resistance by aa substitutions in the core regions (SK et al., data not shown). We speculate from these results that HCV aa substitutions in the core and NS5A regions might affect host immunity by modulating the expression of IFNstimulated genes. By contrast, the long-term responses, SVR and VR, were significantly associated with HCV aa substitutions. In the analysis of SVR, both the aa 70 and aa 91 core substitutions significantly reduced the SVR rate (SK et al., data not shown), and MM viruses, having both core substitutions, were the most tolerant to combination therapy ( Figure 3A ). In addition, no patient infected with HCV coreMM/ISDR0 achieved SVR ( Figure 3B) ; however, we could not assess the association between the number of ISDR aa substitutions and HCV RNA in the present study. In the analysis of VR, 72% of the patients infected with HCV core MM/ISDR0 failed to achieve VR (SK et al., data not shown). Given the varying degrees of viral reduction within patients with the same core and ISDR mutation patterns, we speculated that differences among the VRs were partly dictated by differences in the personal immune response. Recently, the relationship between HCV-related proteins and the IFN signalling pathway has been further elucidated. IFN signalling is activated through the Jak-STAT pathway, inducing the transcription of IFN-stimulated genes, such as double-stranded RNA-dependent protein kinase R, myxovirus resistance 1 and 2′,5′-oligoadenylate synthetase (OAS) [43] [44] [45] [46] [47] [48] [49] [50] . However, in the presence of the HCV core protein and the non-structural protein NS5A, the IFN signal cascade has been known to be suppressed by the interaction with protein kinase R or 2′,5′-OAS and the induction of IFN signal inhibitors, suppressor of cytokine signalling-3 and interleukin-8 [51] [52] [53] [54] [55] . Based on our results and those of other groups, we speculated that the patients who were infected with HCV coreMM/ ISDR0 might be more immunologically suppressed by HCV related proteins. If this speculation is correct, a compound working as a protease inhibitor against HCV non-structural proteins could reduce immune suppression caused by the HCV non-structural proteins. Thus, HCV non-structural proteins might be important potential targets for the development of new therapies.
Among the host factors, γ-GTP level was identified as a predictive factor for both SVR and NVR. Okanoue et al. [28] demonstrated that low-density lipoprotein cholesterol, homeostasis model assessment for insulin resistance and fatty change of liver tissues were significantly associated with SVR. This finding might support our present results because hepatic fatty change is clinically correlated with γ-GTP increase. However, the molecular mechanisms of the relationship between hepatic fatty change and IFN response are still unclear. Further study is needed to clarify this issue.
Our study was performed based on the guidelines of the MHLW of Japan [30] . In the previous studies, substitutions in the HCV core regions and ISDR were analysed separately [18, 19, 28] , and associations were demonstrated between HCV substitutions and IFN response. In the present study, we clarified the association between the IFN response and the combined information of both core and ISDR substitutions. Our study suggests that the combined information of both core and ISDR substitutions might be very useful for predicting the effect of PEG-IFNa2b plus RBV combination therapy.
The main limitation of our study is that some selection biases and confounders, such as serum HCV RNA titres, alcohol consumption, prior antiviral therapy in some patients, and variation in RBV dose, might affect the internal validity of the study. We identified predictive factors for the effect of PEG-IFN-a2b plus RBV combination therapy, especially among patients with high viral loads, whereas the patients with HCV RNA<5.0 log 10 IU/ml were excluded from the study. A previous report showed that ethanol intake of >24 g/day decreased the SVR rate of IFN treatment [31] ; therefore, we excluded patients with a lifetime total ethanol intake of >100 kg to reduce the effect of heavy drinking. We consider that selection of the study participants based on HCV RNA titre and total ethanol intake in our study is valid and appropriate, although we might be unable to disregard the effects of selection bias. A total of 48% of study participants received prior IFN monotherapy or IFN plus RBV combination therapy, but all study participants were naive to PEG-IFN-a2b plus RBV combination therapy. In the present study, SVR rates did not differ significantly (P=0.136) with or without prior antiviral therapy. According to the guidelines of the MHLW of Japan [30] , reduced RBV doses were recommended relative to the universal guidelines. Although the study participants were treated with lower RBV doses, the SVR rate was comparable to the expected rate in Japan and other countries. Thus, we consider potential confounders, such as prior antiviral therapy and RBV dose, might not have a strong influence on our study results.
In conclusion, we analysed the relationship between HCV aa sequence substitutions and the effectiveness of PEG-IFN-a2b plus RBV combination therapy. We identified significant associations among SVR and NVR, HCV core and ISDR substitutions, γ-GTP levels and platelet counts. The poor response of patients infected with HCV coreMM/ISDR0 should be taken into account when considering treatment options.
